Safty and efficacy of autologuous adipose tissue derived mesenchymal stem cell infusion therapy on liver cirrhosis

Safty and efficacy of autologuous adipose tissue derived mesenchymal stem cell infusion therapy on liver cirrhosis - Adipose tissue-derived mesenchymal stem cell therapy

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036136

Enrollment

Registered

2019-03-10

Start date

2019-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

After taking subcutaneous adipose tissue, adpose derived mesencymal stem cell is cultured. Cultured ADSC is infused in the cirrhotic patient autologously.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Liver cirrhosis is diagnosed by CT and clinical data 2.>or= 20 years age 3.>or= Child pugh score 6 4.obtained informed consent

Exclusion criteria

Exclusion criteria: A.alcoholic patients B.sever heart disease C.pregnant patients D.malignant tumor such as HCC E.uncontrolled infectious disease F.impossible to obtain an informed consent I.The patient who primary investigator judged unsuitable

Design outcomes

Primary

Measure	Time frame
General status, D-dimer, FDP, respiratory function, organ function are evaluated at 1,3.7,14,30,90,and 360 days after infusion of ADSC.	—

Countries

Japan

Contacts

Public ContactTomohiko Akahoshi

Department of disaster and emergency medicine Department of disaster and emergency medicine

tomohiko@surg2.med.kyushu-u.ac.jp0926426223

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026